Page 30 - SGH PR REPORT - FEBRUARY 2025

Press Release

Saudi German Health and BD Company sign MoU to

revolutionise microbiology diagnostics

18 February 2025- Saudi German Health (SGH), one of the leading healthcare providers in
the region, signed a Memorandum of Understanding (MoU) with BD Company, a global leader

in advanced healthcare solutions, to transform healthcare services by introducing rapid
diagnostic solutions.

The MoU was signed by Dr. Ahmed Shebl, Group CEO of Saudi German Health and Riza
Mutlak, Business Director at BD - Middle East, North Africa & Turkey, during a ceremony
held recently at SGH’s headquarters in Jeddah. This collaboration is the first of its kind in the
region, setting a new precedent for future innovations in healthcare. With an emphasis on state-
of-the-art laboratory technologies, it will introduce advanced devices such as Bactec, Phoenix,

Epicenter, and MALDI-TOF to significantly enhance diagnostic capabilities and improve
patient care.

The partnership aims to address existing challenges in microbiology by providing rapid and
precise diagnostic solutions, thus establishing new standards for healthcare efficiency. The
launch of these innovative lab devices will allow SGH to provide quicker, more accurate
diagnoses, enhancing patient outcomes and elevating the quality of healthcare throughout the
region.

Makarem Sobhi Batterjee, Vice Chairman of Saudi German Health, stated: “We are proud
to partner with BD Company to introduce these advanced diagnostic devices to our laboratory.
The deployment of these advanced lab devices marks a significant milestone in our ongoing

commitment to providing the highest level of patient care. More importantly, the goals of this
collaboration align seamlessly with our brand ethos of ‘Caring Like Family,’ and we are excited
to integrate these innovations into our processes.”

This partnership offers several key benefits. The MALDI-TOF device uses advanced
technology to quickly and accurately detect a wide range of pathogens, including those that are
difficult to culture, dramatically improving diagnostic accuracy and speed. By identifying the
specific microorganisms responsible for infections, MALDI-TOF ensures the selection of the
most effective antibiotics, mitigating the overuse of broad-spectrum antibiotics and combating

antibiotic resistance.

This partnership is expected to benefit more than 2 million patients annually, allowing the
healthcare provider to deliver quicker, more accurate diagnostics and enhance patient
outcomes. The agreement aims to streamline microbiology diagnostic processes, reducing